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Eph receptor tyrosine kinases (Ephs) function as mo-
lecular relays that interact with cell surface-bound eph-
rin ligands to direct the position of migrating cells.
Structural studies revealed that, through two distinct
contact surfaces on opposite sites of each protein, Eph
and ephrin binding domains assemble into symmetric,
circular heterotetramers. However, Eph signal initia-
tion requires the assembly of higher order oligomers,
suggesting additional points of contact. By screening a
random library of EphA3 binding-compromised eph-
rin-A5 mutants, we have now determined ephrin-A5 res-
idues that are essential for the assembly of high affinity
EphA3 signaling complexes. In addition to the two inter-
faces predicted from the crystal structure of the homol-
ogous EphB2ephrin-B2 complex, we identified a cluster
of 10 residues on the ephrin-A5 E -helix, the E–F loop,
the underlying H -strand, as well as the nearby B–C
loop, which define a distinct third surface required for
oligomerization and activation of EphA3 signaling. To-
gether with a corresponding third surface region iden-
tified recently outside of the minimal ephrin binding
domain of EphA3, our findings provide experimental
evidence for the essential contribution of three distinct
protein-interaction interfaces to assemble functional
EphA3 signaling complexes.
Signaling by Eph receptors (Ephs)1 and their cell surface-
associated ephrin ligands forms an essential part of a highly
conserved molecular mechanism coordinating cell migration
and positioning during normal and oncogenic tissue develop-
ment (1). In general, the path of Eph-expressing cells or axons
is directed through contact-dependent cell-cell adhesion or re-
pulsion (2), whereby competing interactions of neighboring
Eph-expressing cells for ephrin targets govern the final cell
position as the biological outcome (3). Many biological effects
attributed to Eph function require concurrent “forward” signal-
ing in Eph-expressing cells and “reverse” signaling in ephrin-
expressing cells (4, 5). In contrast to the prototypical activation
mechanism of receptor tyrosine kinases, Eph signaling is acti-
vated by the assembly of ephrin/Eph oligomers into large clus-
ters. Ephs are composed of conserved structural modules. They
include a unique N-terminal ephrin binding domain (6–8)
forming a globular -barrel (9), a cysteine-rich linker and epi-
dermal growth factor-like region, and two fibronectin type III
repeats. The cytoplasmic part contains an uninterrupted, tyro-
sine kinase domain (10) and several protein-protein interaction
modules, including Src homology 2-docking sites, a sterile--
motif, and a C-terminal PDZ binding motif (11). Structural
features broadly classify six glycophosphatidyl inositol mem-
brane-anchored ephrins as A-type, which “promiscuously” can
bind and activate nine type-A Ephs, as well as three transmem-
brane ephrins as B-type, which contain conserved cytoplasmic
domains and activate six type-B Ephs (12). It is now clear that
this grouping is likely an oversimplification, and in particular,
EphA4 and EphB2 bind and become activated by both A- and
B-type ephrins (13, 14). This characteristic promiscuity of func-
tionally relevant Eph/ephrin interactions is possibly because of
the high structural conservation of Eph and ephrin binding
domains. Crystal structures of the interacting domains of
EphB2, ephrin-B2, and ephrin-A5 and of their complexes (8, 9,
14, 15) revealed that the initial 1:1 Eph/ephrin contacts (16) are
provided by a deep Eph surface channel formed by -strands
(D, E, G, J, M), which buries the extended, hydrophobic ephrin
G–H loop (8). In the crystal structure of the EphB2ephrin-B2
complex, a second lower affinity heterotetramerization inter-
face facilitates formation of a 2:2 cyclic complex comprising two
Eph/ephrin heterodimers (see Fig. 3). Although comparatively
small, the tetramerization interface is critical for the assembly
of stable, signaling-competent Eph clusters (17), and in agree-
ment with its postulated role of providing subclass binding
specificities (8), is not present in the structure of the
EphB2ephrin-A5 complex (14).
Although there is little doubt that the Eph/ephrin heterotet-
ramers are the essential building block of Eph signaling com-
plexes, downstream signaling requires the assembly of higher
order oligomers (18). In vitro, this is routinely achieved through
Eph activation by preclustered, tetravalent ephrin-Fc fusion
proteins (19). The available crystal structures leave unclear
how Ephs and ephrins assemble into the oligomeric signaling
* This work was supported by grants from the National Health and
Medical Research Council of Australia (284428, 234707) (to M. L. and
A. W. B.) and National Institutes of Health Grant RO1-NS38486 (to
D. B. N.). The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org)
contains supplemental Table 1.
The atomic coordinates and structure factors (code 1SHX) have been
deposited in the Protein Data Bank, Research Collaboratory for Struc-
tural Bioinformatics, Rutgers University, New Brunswick, NJ (http://
www.rcsb.org/).
§ These authors made equal contributions to this work and are thus
regarded as joint first authors.
‡‡ To whom correspondence should be addressed: Dept. of Biochem-
istry and Molecular Biology, P.O. Box 13D, Monash University, Victoria
3800, Australia. Tel.: 613-9905-3738; Fax: 613-9905-3726; E-mail:
martin.lackmann@med.monash.edu.au.
1 The abbreviations used are: Ephs, Eph receptors; TEV, tobacco
etch virus; HEK, human embryonic kidney; w/t, wild-type; IP,
immunoprecipitation.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 28, Issue of July 15, pp. 26526–26532, 2005
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org26526
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
complexes that are required for biological responses (11, 18)
and suggest the involvement of Eph/ephrin contact regions
outside the crystallized domains. Indeed, earlier studies indi-
cated the presence of ephrin-independent Eph/Eph contacts
located C-terminally of the globular domain that are important
for EphA3 function (7). Furthermore, a recent analysis of eph-
rin-A5 binding-compromised EphA3 mutants revealed, in ad-
dition to the two structurally defined ephrin binding sites, a
third functional binding interface outside the crystallized do-
main (17). This site, although contributing only modestly to
ligand binding, is essential for receptor phosphorylation, re-
cruitment of signaling molecules, and downstream responses,
supporting the notion that the tetrameric Ephephrin complex
observed in the crystal structure is necessary (but not suffi-
cient) for signaling. The position of the newly identified binding
site within the cysteine-rich linker that connects the ephrin
binding and Eph-Eph dimerization domains suggests that eph-
rin binding may cause a reorientation of Ephs that facilitates
their assembly into oligomeric clusters (17).
We have now applied the same random mutagenesis ap-
proach previously used to identify ephrin-A5-interacting resi-
dues in EphA3 to assign the molecular determinants of eph-
rin-A5 that mediate EphA3 binding. In this case, the recently
elucidated crystal structure of ephrin-A5 in complex with
EphB2 (14) allowed the selection, structural alignment, and
functional analysis of EphA3 binding-compromised ephrin-A5
mutants from a library of random point mutants spanning the
whole N-terminal receptor binding domain of ephrins. Our
analysis revealed a number of critical residues that confirm the
two Eph binding sites shown in the crystal structure of the of
the EphB2ephrin-B2 complex (8). We also uncover a potential
third Eph-interacting surface, the existence of which had been
implied by the EphA3 mutagenesis study (17). This new site,
which likely mediates Eph/ephrin clustering interactions, in-
cludes the protruding ephrin-A5 E -helix and E–F loop, the
underlying H -strand, as well as the nearby B–C loop. Its
location, between the dimerization and tetramerization sites, is
consistent with a corresponding interaction surface on EphA3
that is closely adjacent to the Eph globular domain. Kinetic and
functional analysis of representative mutants confirms the no-
tion that engagement of each of the three identified Eph bind-
ing sites of ephrin-A5 is required to elicit cell-morphological
responses in EphA3-expressing cells.
MATERIALS AND METHODS
Reagents
The anti-EphA3 monoclonal antibody, IIIA4, and the affinity-puri-
fied rabbit polyclonal antibodies were previously described (16, 20).
Other antibodies and reagents were from Transduction Laboratories
(anti-CrkII), Upstate Biotechnology (4G10), New England Biolabs
(P-Tyr100), Jackson Laboratories (horseradish peroxidase-conju-
gated anti-mouse antibodies), and Bio-Rad (horseradish peroxidase-
conjugated anti-rabbit).
Protein Expression and Purification
EphA3 and Ephrin-A5-Fc Fusion Proteins—Recombinant protein
containing the EphA3 extracellular domain fused to the human IgG1
hinge and Fc regions (EphA3-Fc) was prepared as described previously
(17). For the expression of ephrin-A5-Fc, we prepared a cDNA encoding
ephrin-A5 (GenBankTM accession number NM_001962) residues Met1–
Ala204, followed by the consensus sequence ENLYFQG corresponding to
the protease cleavage site of the tobacco etch virus (TEV) protease,
followed by the IgG1 hinge and Fc regions of human IgG1. The product
was cloned in-frame into the unique BamHI site of the pIgBOS vector.
EphA3-Fc and ephrin-A5/TEV-Fc DNA were stably transfected into
Chinese hamster ovary cells, and the proteins were purified from im-
munoglobulin-depleted cell culture supernatants on protein-A-Sepha-
rose and ion exchange MonoQ columns under conditions described
previously (22). For large scale protein production, ephrin-A5-Fc-ex-
pressing cells were grown in IgG-free culture medium using cellulose
acetate hollow fiber bioreactors (Cellex Biosciences, Minneapolis, MN)
as described previously (14).
Yeast Ephrin-A5 Expression—The ephrin-A5 fragment (Gln21–
Ser199) was generated by PCR from the wild-type ephrin-A5 cDNA
(GenBankTM accession number NM_001962) in pBluescript using prim-
ers corresponding to nucleotides 344–362 and 862–879 and cloned into
a modified (17) YEpFLAG-1 (Sigma) yeast expression vector. This ex-
pression vector positions the ephrin coding sequence between N- and
C-terminal FLAG and Myc epitopes, respectively, allowing detection of
the full-length protein with anti-FLAG antibody (M2, Sigma) and/or the
anti-Myc antibody (9E10, a generous gift from Dr. D. Huang, Walter
and Eliza Hall Institute, Melbourne, Australia).
Random Mutagenesis
Random point mutants of the ephrin-A5 extracellular domain were
created using non-stringent PCR (17, 23). Conditions were optimized to
yield 3–4 mutations or 1–3 amino acid changes/clone, so that 500
independent clones with some 1000 mutated amino acid residues pro-
vided a four-fold mutational coverage of the target sequence. A library
of random point mutants was initially prepared in Escherichia coli. The
plasmid cDNAs from pooled colonies (17,000) were then transfected
into the Saccharomyces cerevisiae strain BJ3505, and yeast colonies
expressing mutant ephrin-A5 proteins were screened with monoclonal
antibodies against the Myc (9E10) and FLAG (M2) epitopes and with
EphA3-Fc as described previously (17). Individual filters from each set
of replicates were probed with horseradish peroxidase-conjugated anti-
mouse and anti-human IgG antibodies (Dako). Colonies showing re-
duced EphA3-Fc binding were recovered and DNA extracted for se-
quence analysis of the ephrin-A5 (XhoI-BglII) inserts.
Site-directed Mutagenesis and Transient Protein Expression
To determine relevant mutations in critical ephrin-A5 clones con-
taining 1 amino acid change, individual mutations were introduced
into the ephrin-A5/TEV-Fc mammalian expression vector by site-di-
rected mutagenesis (QuikChange mutagenesis kit, Stratagene). Follow-
ing transient transfection into HEK293T cells (FuGENE 6, Roche Ap-
plied Sciences), mutant and wild-type (w/t) ephrin-A5/TEV-Fc proteins
were purified from culture supernatants using protein-A and ion ex-
change chromatography as described under “EphA3 and Ephrin-A5-Fc
Fusion Proteins.” Protein expression was assessed by Western blot
(anti-human IgG horseradish peroxidase) and by BIAcore analysis us-
ing sensor chips with parallel surfaces containing immobilized EphA3,
anti-human IgG antibody, and single chain ephrin-A5.
Surface Plasmon Resonance Analysis
Analysis of protein interactions by surface plasmon resonance was
carried out on a BIAcore 2000 biosensor (BIAcore) as described previ-
ously (17). Purified wild-type and mutant ephrin-A5 extracellular do-
main proteins were analyzed on parallel EphA3-Fc- and ephrin-A5-
derivatized CM5 sensor chips (BIAcore 2000 optical biosensor, BIAcore
AB, Sweden). The concentrations of high pressure liquid chromatogra-
phy-purified proteins were determined from absorbance measurements
at 215 nm. Samples of purified ephrin-A5 extracellular domain (62.5–
1000 ng/ml) were analyzed in each assay. Interaction kinetics were
evaluated from seven serial dilutions of each sample by Global Analysis
using the BIAevaluation software (version 3.1).
TABLE I
Summary of the random mutagenesis screen
Yeast colonies transfected with YEpFLAG-1 encoding mutant, solu-
ble ephrin-A5 proteins were selected by probing three consecutive ni-
trocellulose filters containing absorbed proteins from individual yeast
colonies with anti-FLAG and anti-Myc antibodies, EphA3-Fc, and with
appropriate secondary antibodies. Only clones secreting ephrins with
N- and C-terminal FLAG and Myc epitopes, respectively, were further
considered. Approximately similar numbers of colonies secreting
EphA3-binding () or -binding-compromised () mutant ephrins were
analyzed. As some clones express ephrin-A5 proteins with more than
one mutation (see “Materials and Methods”), the number of mutations
is  the number of colonies.
FLAG/Myc
epitope
present
EphA3
binding
No. of
mutations
analyzed
% of total
analyzed
mutations
No. of
colonies
% of total
colonies
analyzed
  77 48.5 40 48
  82 51.5 44 52
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FIG. 1. Location of ephrin-A5 point mutants within the amino acid sequences of human A-type ephrins and ephrin-B2. a, the
alignment gaps were adopted from a ClustalX (1.81) multiple sequence alignment of all known ephrin sequences, excluding Drosophila ephrin.
Residues that are conserved in four or more ephrins are shaded gray. Ephrin-A5 point mutants not affecting binding and mutants that compromise
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Cell Manipulations, Immunoprecipitation, Western Blotting,
and Microscopy
The HEK293 cells that were stably transfected with full-length
EphA3 have been described previously (24, 25). Following stimulation
of these cells for 10 min with 1.5 g/ml preclustered, w/t, or mutant
ephrin-A5-Fc, Triton X-100 cell lysates were prepared, and even por-
tions (50% v/v) were subjected to immunoprecipitation (IP) with anti-
EphA3 monoclonal antibody IIIA4 affinity beads or anti-CrkII mono-
clonal antibody/protein-A-Sepharose as described previously (24). The
anti-CrkII IPs and 1⁄3 of the anti-EphA3 IPs were probed with anti-
EphA3 and anti-phosphotyrosine antibodies, respectively. To assess
even gel loading, 8% (v/v) of each anti-EphA3 IP was probed with
anti-EphA3 antibodies.
RESULTS
Expression Library Screen for EphA3 Binding-defective Eph-
rin-A5 Mutants—To define critical Eph binding and signal
initiation residues in ephrin-A5, we subjected most of the ex-
tracellular domain (residues Gln21–Ser199) to random mu-
tagenesis, excluding only the N-terminal signal sequence and
C-terminal unstructured residues. The experimental condi-
tions, previously optimized to assign critical EphA3 surfaces
(17), resulted in a four-fold mutational coverage of the eph-
rin-A5 sequence. This corresponds to a library of some 1000
mutants, which are randomly distributed across the entire
target sequence. Only mutations that had generated full-length
secreted proteins containing both the N-terminal FLAG and
the C-terminal Myc tags (assayed with anti-FLAG and anti-
antibodies) were selected for further analysis (Table I). A total
of 84 colonies with an average of two amino acid substitutions
were sequenced. The ephrin-A5 proteins secreted from these
colonies were further assayed for binding of EphA3-Fc, reveal-
ing that 44 clones produced ephrins that retained EphA3 bind-
ing capacity, whereas 40 mutants had lost this capacity.
The EphA3 Binding Mutants Define Three Distinct Contact
Surfaces—For an initial assessment of their functional rele-
vance, we mapped these mutations onto the wild-type se-
quences of human A-type ephrins, as well as ephrin-B2 (Fig.
1a), all of which bind with varying affinities to EphA3 (16, 26).
A total of 33 amino acid substitutions that affect the EphA3
binding map to the crystallized portion of ephrin-A5, whereby
most (21/33) of the corresponding residues are conserved in five
or all of the six aligned ephrins. Some 19 of these 21 mutations
are located within (or immediately adjacent to) the proposed
heterodimerization (12/33) or heterotetramerization (7/33) mo-
lecular surfaces. Importantly, a cluster of 5 mutations that
compromised EphA3 binding was found within the highly con-
served sequence motif YY(F)Y(I)IS on the “H” -strand. This
strand packs against the protruding E -helix and the long E–F
loop that harbor 4 additional mutations. Together with the
nearby B–C loop, containing one mutation, these secondary
structure elements generate an ephrin surface positioned be-
tween the dimerization and tetramerization interfaces (Fig. 1b;
see also Fig. 3), which is not in direct Eph contact in the
Eph-B2/ephrin-B2 structure, (14). The clustered localization of
these residues suggests that they define a distinct third inter-
action site of the EphA3ephrin-A5 complex.
For comparison, we also mapped the 44 amino acid substi-
tutions that did not alter the binding to EphA3. Only 9 of the 44
affected conserved residues (in at least four of the aligned
ephrins), and 7 of these were conservative substitutions (Asp3
Asn, Ser3 Thr, Leu3 Ile, or Phe3 Tyr). Notably, mutations
in 16 (of the 24) juxtamembrane ephrin-A5 residues did not
affect EphA3 binding, confirming that this unstructured region
is not involved in Eph/ephrin interactions.
Kinetic Analysis of Selected Ephrin-A5 Mutants—The map-
ping of the amino acid substitutions onto the ephrin-A5 struc-
ture in the context of known Eph/ephrin contacts allowed us to
select six mutants for functional analysis, including represen-
tatives for each of the previously defined interfaces. We intro-
duced these mutations into an expression vector encoding eph-
rin-A5 fused to the Fc part of human IgG and separated by an
engineered TEV protease cleavage site, allowing production of
monomeric ephrin-A5 as well as dimeric Fc-fusion derivatives
from the same expression construct. For surface plasmon res-
onance analysis, monomeric ephrins were released by TEV
cleavage (Fig. 2a, inset), and their binding to the EphA3 ectodo-
main or bovine serum albumin as non-relevant control proteins
was tested on parallel BIAcore sensor surfaces (Fig. 2a).
The kinetic analysis of the ephrin-A5 mutants revealed that
a substitution of the G–H loop residue Thr122 with an alanine
profoundly reduces the association rate and increases the dis-
sociation rate of the EphA3/ephrin-A5 interaction (Table II),
resulting in marginal micromolar affinity binding (Fig. 2a).
This observation confirms previous findings, indicating that
the major contribution to the binding affinity is provided by
docking of the ephrin G–H loop into the ligand binding Eph
channel at the heterodimerization interface (8, 17). By compar-
ison, amino acid substitutions on the ephrin “D” -strand
(Gly963 Arg and Lys983 Asn), which binds along the upper
convex surface of the receptor at the Eph/ephrin dimerization
interface, affect EphA3/ephrin-A5 interaction less dramati-
cally, yielding only a 3–4-fold decrease in the binding affinity
(41 and 60 nM, respectively).
Not surprisingly, a similarly pronounced effect upon EphA3
recognition and binding was observed for the mutation
Asn373 Ile, located at the base of the ephrin A–B loop at the
tetramerization interface. Its almost 10-fold affinity drop from
13 to 122 nM was primarily the result of a substantially reduced
association rate of the mutant protein (2.8  104 M s1) com-
pared with w/t ephrin-A5 (1.1  106 M s1, Table II).
Importantly, two of the point mutations, Phe1373 Ser and
Ile1393 Thr, located between the previously characterized
dimerization and tetramerization surfaces (see Fig. 1b), affect
EphA3 binding to an extent comparable with that of the dimer-
ization interface mutations Gly963 Arg and Lys983 Asn.
Specifically, the mutated residues map to the conserved H-
strand, where they mediate its packing against the “E” helix at
the ephrin-A5 molecular surface. Phe137 and Ile139 are far from
the dimerization (20 Å of distance to the tip of the G–H loop)
and tetramerization interfaces, and it is doubtful their muta-
tion would affect the structure of these ephrin binding sites.
More likely, they would only affect the local molecular surface
and, in particular, the positioning and/or conformation of the
protruding E–F loop and E helix relative to the underlying
-barrel scaffold. We postulate that this surface region, to-
binding to EphA3 (maximally two mutations/residue shown) are indicated under the ephrin-A5 sequence in blue and red bold lowercase letters,
respectively. Red triangles above the sequences indicate point mutants that were subjected to detailed functional analysis. The N-terminal
sequences, not present in the crystal structures of ephrin-B2 (8) and ephrin-A5 (14), are given in lowercase lettering. Secondary structure elements
according to the ephrin-B2 and ephrin-A5 crystal structures are illustrated as arrows for -sheets and waved rectangles for helices. Purple and
yellow boxes underlining the ephrin-B2 sequence indicate residues in the dimerization and tetramerization interfaces, respectively. Above the
alignment, in green letters, is indicated whether the residues are surface exposed (e), buried (b), or partially buried (p). A list of the surface-exposed
areas of all ephrin-A5 residues is provided as supplemental Table 1. b, molecular surface of ephrin-A5 (Protein Data Bank code 1SHX) highlighting
all residues identified in this study that harbor Eph binding-defective mutations. The mutated residues in the previously characterized
heterodimerization interface are in magenta, the mutated residues in the heterotetramerization interface are in yellow, and all other mutated
residues are in green.
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gether with the nearby B–C loop constitutes an additional
(third) Eph/ephrin interface (Fig. 1b, green) that was not ap-
parent in the crystal structures of the complex of their minimal
interaction domains.
Reduced EphA3 Binding Affinities Affect Ephrin-A5-induced
Biological Responses—We evaluated whether the reduced
binding affinities of the ephrin-A5 mutants cause correspond-
ing effects on EphA3 signaling and downstream cell-morpho-
logical responses by assaying typical ephrin-A5-triggered re-
sponses, including cell rounding and detachment (Fig. 2 b, c),
as well as EphA3 phosphorylation and recruitment of CrkII
(Fig. 2d). Purified w/t or mutant ephrin-A5-Fc fusion proteins
were used for these experiments, and their binding avidities
to EphA3 were confirmed by plasmon resonance analysis
(Table II).
As described previously (24), exposure of stably EphA3-
transfected HEK293 (EphA3/HEK293) cells to preclustered
ephrin-A5-Fc results in dose-dependent cell rounding (Fig. 2b)
and detachment (Fig. 2c). By contrast, treatment of parallel
cultures of EphA3/HEK293 cells with the most severely af-
fected mutant, Thr1223 Ala, changed neither the cell morphol-
ogy nor cell adhesion, as compared with untreated control cells.
In agreement, CrkII recruitment was not noticeable in these
cells. Interestingly, EphA3 phosphorylation was only reduced
but not ablated, in agreement with previous findings that
EphA3 phosphorylation and Crk recruitment are not necessar-
ily linked (24). Similarly, exposure of cells to ephrin-A5-Fc
mutated in the tetramerization interface (Asn373 Ile) or the H
-strand (Phe1373 Ser) only weakly modulated cell morphol-
ogy and cell adhesion. CrkII recruitment and EphA3 phospho-
rylation were affected for both mutants to similar degrees,
suggesting a possible role also of the third ephrin interface for
the overall stability of the Eph/ephrin signaling complex. To-
gether, these findings confirm the functional importance of the
heterodimerization and the heterotetramerization interfaces
for EphA3 binding and activation by ephrin-A5 and, in addi-
tion, suggest the essential involvement of a third previously
unidentified Eph/ephrin contact site.
DISCUSSION
A unique feature of Eph signaling is the assembly of oligo-
meric signaling complexes (18, 21), which are required to trans-
late cell surface densities of cognate ephrins into graded cell-
morphological responses of Eph-expressing cells (2, 3).
Crystallographic analysis of the Eph and ephrin interaction
domains unraveled a heterotetrameric complex as an essential
building block (8) but also suggested that additional molecular
contacts, not apparent in the crystal structures, must be
formed to assemble functional signaling clusters.
Here we have identified a cluster of 10 ephrin-A5 residues
that are part of the E -helix and E–F loop, the underlying H
-strand, as well as the nearby B–C loop. Together they form a
rugged, convex surface between the heterodimerization and the
heterotetramerization domains, providing a third EphA3 inter-
action site that seems essential for EphA3 signal initiation. In
our study, we exploited a library screening approach, designed
previously to assign the molecular determinants of EphA3 re-
quired for high affinity ephrin binding and formation of func-
tional signaling complexes (17). The strategy is based on the
design of a library of mutations randomly distributed across
the target sequence, providing an unbiased mutational cover-
age of the target protein. We argue that, in combination with
antibody and protein binding assays as functional read-outs for
secreted and (by inference) correctly folded mutant proteins
with binding defects for the interaction partner, this approach
ensures identification of all relevant interaction sites. Indeed,
repeated amino acid substitutions of the same residue through-
FIG. 2. Functional analysis of selected EphA3 binding-compro-
mised ephrin-A5 mutants. Ephrin-A5-Fc fusion proteins (w/t or con-
taining indicated amino acid substitutions) were purified on protein-A-
Sepharose from supernatants of transiently expressed HEK293 cells
and subjected to kinetic analysis by surface plasmon resonance (a), or to
cell-based functional analysis (b–d). a, for BIAcore assays, TEV-cleaved
proteins were purified by ion exchange high pressure liquid chromatog-
raphy and analyzed by SDS-PAGE/silver staining (inset) prior to anal-
ysis on a sensor chip containing the EphA3 exodomain. BIAcore sen-
sorgrams illustrate binding of ephrin-A5 (w/t or mutant as indicated) at
the maximal tested concentration (50 nM, in color) and the calculated
theoretical fit (stippled line) to a Langmuir interaction. b, EphA3-
HEK293 cells cultured on fibronectin-coated glass slides were exposed
to preclustered, w/t, and mutant ephrin-A5-Fc for 10 min. Cell-morpho-
logical and actin-cytoskeletal responses of fixed rhodamine/phalloidin-
stained cells were monitored by confocal microscopy. Scale bar  20
m. c, adhesion of cells exposed to preclustered w/t ephrin-A5-Fc or
mutants, as indicated, was determined from the area covered by cells in
a minimum of three microscopic fields (selected by a blinded observer).
Mean and standard deviation from a minimum of three independent
experiments is shown. d, in parallel experiments, cells were exposed to
w/t or mutant ephrin-Fc, equal portions of cell lysates subjected to IPs
with anti-EphA3 or anti-CrkII antibodies and probed with anti-EphA3
and anti-phosphotyrosine antibodies as indicated under “Materials and
Methods.” The immunoblots (W/B) from three independent experi-
ments were scanned, and relative intensities (mean and S.D.) of indi-
vidual bands are illustrated together with representative examples of
the immunoblots. To assess even gel loading, a sample of the anti-
EphA3 IPs was probed with anti-EphA3 antibodies as indicated in the
bottom panel.
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out the target sequence (Fig. 1a) indicate that representative
mutants across the complete ephrin-A5 sequence were identi-
fied. Our results reveal that, in addition to the known high and
low affinity heterodimerization and tetramerization sites, an
additional Eph/ephrin interface may be required for receptor
activation. Specifically, we postulate that the ephrin-A5 sur-
face (Fig. 1b, green), located between the previously identified
heterodimerization (Fig. 1b, purple) and tetramerization (Fig.
1b, yellow) sites, interacts with the cysteine-rich linker of
EphA3 (17) to facilitate assembly of tetrameric complexes (Fig.
3) into higher order signaling aggregates. Overall, 30 of the 33
amino acid positions (91%) with function-diminishing muta-
tions are located to these three proposed EphA3 contact sites.
It is interesting that the conserved “YFYIS” motif of the
H-strand, which contains 5 of the 10 mutations defining the
newly identified Eph-interaction region, is largely buried and
mediates packing of the surface E helix and E–F loop against
the -barrel scaffold (14). Thus, it is likely that EphA3 does not
interact directly with the ephrin-A5 H-strand but rather with
the E helix, the E–F loop, and the B–C loop, which harbor
another five receptor mutations. A likely explanation for the
fact that we identified a disproportional number of mutations
in the H-strand is that single amino acid substitutions there
affect the architecture of the whole overlying E helix and E–F
loop, thus providing disproportionately large alterations of the
local molecular surface. Although we believe that the H-strand
mutations will not affect the heterodimerization and heterotet-
ramerization interfaces, we cannot completely rule out this
possibility in the absence of detailed structural data. However,
we are confident that these mutations do not affect the overall
folding and stability of ephrin-A5 as they yield biochemically
well behaved proteins that still maintain, to a significant de-
gree, their receptor recognition properties.
Importantly, the assignment of seven function-affecting eph-
rin-A5 mutations to positions corresponding to the heterotet-
ramerization interface of ephrin-B2 (Fig. 3) verifies that the
high affinity ephrin-A5EphA3 complex has the same heterotet-
rameric architecture as the structurally elucidated EphB2
ephrin-B2 complex. In agreement with this conclusion, the
reduction in EphA3 binding affinity and biological activity ob-
served for the heterotetramerization surface substitution,
Asn373 Ile (9-fold reduced affinity, reduced EphA3 activa-
tion), and the dimerization surface substitution, Thr1223 Ala
(50-fold reduced affinity, loss of EphA3 activation), match the
effects that would be expected for mutations of these low and
high affinity binding sites, respectively. In this context, it is
interesting to note that, despite only moderate effects on
binding affinity, mutations in the newly identified (third)
interaction site substantially reduce the capacity of ephrin-A5
to trigger EphA3 phosphorylation, Crk recruitment, and cell
rounding.
We propose that the structural role of the newly identified
interaction surface in ephrins is to bind the cysteine-rich do-
main of an Eph receptor from an adjacent Eph/ephrin tetramer
(Fig. 3), thus assembling higher order signaling clusters. The
fairly mild effect of the analyzed mutations on EphA3 binding
suggests that engagement of this interface, similar to the tet-
ramerization interface, relies on pre-existing, high affinity
Eph/ephrin contacts. We speculate that the additional contact
through the third interface triggers an EphA3 conformation
that favors Eph/Eph oligomerization. It should be noted that it
is also possible to model an Ephephrin tetrameric complex
where all three contact sites are contained within the four
interacting Eph and ephrin molecules. In this case, formation
of higher order clusters would rely solely on Eph-Eph interac-
tions, a notion supported by the finding that Eph receptors
lacking the whole ephrin binding domain are effectively re-
cruited into Eph signaling clusters (25). Thus, a detailed un-
derstanding of the precise molecular architecture of the func-
tional Eph/ephrin signaling clusters requires crystallographic
analysis of a complex between their complete extracellular
domains.
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Supplemental data, Table 1. Analysis of  surface accessible areas of ephin-A5 residues  
 
     VAL   28    136.00     ALA   29     80.00     ASP   30     97.00 
     ARG   31     99.00     TYR   32     33.00     ALA   33     49.00 
     VAL   34      1.00     TYR   35    115.00     TRP   36      1.00 
     ASN   37     34.00     SER   38     50.00     SER   39    101.00 
     ASN   40     24.00     PRO   41     84.00     ARG   42    114.00 
     PHE   43      4.00     GLN   44    129.00     ARG   45    172.00 
     GLY   46     36.00     ASP   47     65.00     TYR   48      9.00 
     HIS   49    107.00     ILE   50     10.00     ASP   51     62.00 
     VAL   52      0.00     CYS   53     28.00     ILE   54     37.00 
     ASN   55     80.00     ASP   56      5.00     TYR   57     68.00 
     LEU   58      0.00     ASP   59     10.00     VAL   60      0.00 
     PHE   61     39.00     CYS   62      8.00     PRO   63      3.00 
     HIS   64     68.00     TYR   65     51.00     GLU   66    136.00 
     ASP   67    140.00     SER   68     93.00     VAL   69     39.00 
     PRO   70     60.00     GLU   71    153.00     ASP   72    146.00 
     LYS   73    152.00     THR   74     11.00     GLU   75     33.00 
     ARG   76     63.00     TYR   77     21.00     VAL   78     21.00 
     LEU   79      0.00     TYR   80     34.00     MET   81      9.00 
     VAL   82     14.00     ASN   83     69.00     PHE   84     99.00 
     ASP   85    115.00     GLY   86      8.00     TYR   87     14.00 
     SER   88     62.00     ALA   89     70.00     CYS   90     25.00 
     ASP   91     39.00     HIS   92     67.00     THR   93    115.00 
     SER   94     92.00     LYS   95    141.00     GLY   96     47.00 
     PHE   97    104.00     LYS   98    108.00     ARG   99     40.00 
     TRP  100     16.00     GLU  101     76.00     CYS  102      2.00 
     ASN  103     52.00     ARG  104    132.00     PRO  105     16.00 
     HIS  106     75.00     SER  107     11.00     PRO  108    128.00 
     ASN  109    152.00     GLY  110     25.00     PRO  111     43.00 
     LEU  112     43.00     LYS  113     99.00     PHE  114     42.00 
     SER  115     52.00     GLU  116      6.00     LYS  117     51.00 
     PHE  118      0.00     GLN  119     44.00     LEU  120    105.00 
     PHE  121    138.00     THR  122     18.00     PRO  123     95.00 
     PHE  124    149.00     SER  125    111.00     LEU  126    173.00 
     GLY  127     38.00     PHE  128     55.00     GLU  129     82.00 
     PHE  130      3.00     ARG  131    144.00     PRO  132     33.00 
     GLY  133     41.00     ARG  134    104.00     GLU  135    101.00 
     TYR  136     25.00     PHE  137     18.00     TYR  138      1.00 
     ILE  139      0.00     SER  140      4.00     SER  141     18.00 
     ALA  142     30.00     ILE  143     53.00     PRO  144     59.00 
     ASP  145     76.00     ASN  146    100.00     GLY  147     71.00 
     ARG  148    181.00     ARG  149    202.00     SER  150     96.00 
     CYS  151     31.00     LEU  152     18.00     LYS  153     26.00 
     LEU  154      1.00     LYS  155     64.00     VAL  156      0.00 
     PHE  157     64.00     VAL  158      0.00     ARG  159     68.00 
     PRO  160     43.00     THR  161    105.00     ASN  162    114.00 
     SER  163     64.00     CYS  164     42.00     MET  165    239.00 
 
Supplementary Table 1. The surface accessible areas (in Å2) of all ephrin-A5 residues present in the 
crystal structure, PDBID: 1SHX were calculated with the program CCP4 (Collaborative Computational 
Project, The CCP4 suite: programs for X-ray crystallography. Acta Crystallogr. D 50, pp. 760-763, 1994), 
and are listed together with the sequence position. 
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